Patents Assigned to Domantis Limited
-
Publication number: 20110159003Abstract: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: January 24, 2007Publication date: June 30, 2011Applicant: Domantis LimitedInventors: Ian Tomlinson, Allart Adriaan Stoop, Armin Sepp, Inusha De Silva, Caroline J. Dimech, Malgorzata Pupecka, Rudolf M.T. De Wildt, Philip D. Drew, Steve Holmes
-
Publication number: 20110097339Abstract: The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain.Type: ApplicationFiled: June 18, 2009Publication date: April 28, 2011Applicant: Domantis LimitedInventors: Steven Holmes, Carrie Enever, Steven Grant, David Sansom
-
Patent number: 7927596Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: April 19, 2011Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Publication number: 20110086019Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: April 14, 2011Applicant: Domantis LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Armin Sepp
-
Patent number: 7846721Abstract: Disclosed is a polynucleotide molecule comprising a promoter operably linked to a nucleic acid sequence encoding a GAS1 secretion signal peptide, wherein said promoter is not a rhamnose promoter.Type: GrantFiled: July 27, 2006Date of Patent: December 7, 2010Assignee: Domantis LimitedInventor: Rudolph M. T. DeWildt
-
Publication number: 20100291103Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 3, 2008Publication date: November 18, 2010Applicant: Domantis LimitedInventors: Micheal Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20100266616Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 4, 2008Publication date: October 21, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100260763Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: October 14, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100254995Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 3, 2008Publication date: October 7, 2010Applicant: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Thomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20100254972Abstract: The invention relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the GI tract or pulmonary tissue of a human. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, combining the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, eg for treating disease or conditions of GI tract or pulmonary tissue in humans.Type: ApplicationFiled: June 3, 2008Publication date: October 7, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100247515Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 4, 2008Publication date: September 30, 2010Applicant: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent S. Jespers, Thil Dinuk Batuwangala
-
Publication number: 20100092482Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: ApplicationFiled: May 1, 2009Publication date: April 15, 2010Applicant: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7696320Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: GrantFiled: January 11, 2006Date of Patent: April 13, 2010Assignee: Domantis LimitedInventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M. T. de Wildt
-
Publication number: 20100056439Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: December 5, 2006Publication date: March 4, 2010Applicant: DOMANTIS LIMITEDInventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward
-
Publication number: 20100021473Abstract: Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the ligands described further comprise a toxin. In other embodiments, the ligands further comprise half-life extending moieties. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: December 5, 2006Publication date: January 28, 2010Applicant: DOMANTIS LIMITEDInventors: Elena De Angelis, Steve Holmes, Ian Tomlinson, Eric Yi-Chun Huang, Lucy J. Holt, Claire E. Everett
-
Publication number: 20090258012Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.Type: ApplicationFiled: March 24, 2009Publication date: October 15, 2009Applicant: Domantis LimitedInventors: Olga Ignatovich, Rudolf Maria Theodora de Wildt, Benjamin Woolven, Steven Grant, Philip C. Jones, Amrik Basran, Neil Brewis
-
Publication number: 20090203542Abstract: The present invention concerns a method for the selection of a virus comprising the steps of: (a) providing a virus encoding and displaying a fusion polypeptide, said fusion polypeptide comprising a heterologous polypeptide inserted into the sequence of a viral coat protein polypeptide, wherein said virus comprises a cleavable site located within a displayed polypeptide; (b) exposing the virus to a cleaving agent; (c) propagating the virus comprising intact fusion protein.Type: ApplicationFiled: October 7, 2008Publication date: August 13, 2009Applicant: Domantis LimitedInventors: Lutz Reichmann, Peter Kristensen, Jean-Luc Jestin, Gregory Paul Winter
-
Patent number: 7563443Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: April 8, 2005Date of Patent: July 21, 2009Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Publication number: 20090176209Abstract: The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.Type: ApplicationFiled: January 17, 2007Publication date: July 9, 2009Applicant: Domantis LimitedInventors: Armin Sepp, Andrew Griffiths
-
Publication number: 20090111745Abstract: Drug fusions and conjugates that contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: ApplicationFiled: December 1, 2005Publication date: April 30, 2009Applicant: DOMANTIS LIMITEDInventor: Ian M. Tomlinson